Biota Pharma Europe Limited

Quick facts

Phase 2 pipeline

• BTA-C585 oral capsule · Virology/Infectious Disease
  BTA-C585 is an oral antiviral agent that inhibits viral replication through targeting of viral proteases or polymerases.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biota Pharma Europe Limited portfolio CI brief
• Biota Pharma Europe Limited pipeline updates RSS

Related

• Sector hub: All tracked pharma companies